Published in Cancer Sci on June 18, 2014
Retracted Up-regulation of miR-130b expression level and down-regulation of miR-218 serve as potential biomarker in the early detection of human osteosarcoma. Diagn Pathol (2015) 1.10
Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. Cancer Sci (2015) 1.04
MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. Br J Cancer (2015) 1.01
Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer. Br J Cancer (2015) 0.99
MicroRNA expression signature of oral squamous cell carcinoma: functional role of microRNA-26a/b in the modulation of novel cancer pathways. Br J Cancer (2015) 0.99
MicroRNA-218 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma cells by targeting BMI1. Int J Mol Med (2015) 0.93
An update on the LIM and SH3 domain protein 1 (LASP1): a versatile structural, signaling, and biomarker protein. Oncotarget (2015) 0.93
The impact of pri-miR-218 rs11134527 on the risk and prognosis of patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol (2014) 0.85
Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma. J Hum Genet (2015) 0.82
Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer. Int J Oncol (2016) 0.82
microRNA-32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells. Oncol Lett (2015) 0.81
miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. Cell Death Dis (2017) 0.78
MiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy. Int J Clin Exp Pathol (2015) 0.78
Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma. Int J Oncol (2016) 0.76
Regulation of matrix metalloproteinases (MMPs) expression and secretion in MDA-MB-231 breast cancer cells by LIM and SH3 protein 1 (LASP1). Oncotarget (2016) 0.76
Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer. J Hum Genet (2016) 0.76
Differentially Expressed MicroRNAs in Meningiomas Grades I and II Suggest Shared Biomarkers with Malignant Tumors. Cancers (Basel) (2016) 0.75
Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer. Oncotarget (2016) 0.75
XIAP 3'-untranslated region as a ceRNA promotes FSCN1 function in inducing the progression of breast cancer by binding endogenous miR-29a-5p. Oncotarget (2017) 0.75
Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals. Anticancer Agents Med Chem (2016) 0.75
Prognostic significance of low microRNA-218 expression in patients with different types of cancer: Evidence from published studies. Medicine (Baltimore) (2016) 0.75
Tumor-suppressing roles of miR-214 and miR-218 in breast cancer. Oncol Rep (2016) 0.75
MicroRNA-29a plays a suppressive role in non-small cell lung cancer cells via targeting LASP1. Onco Targets Ther (2016) 0.75
MicroRNA-218 modulates activities of glioma cells by targeting HMGB1. Am J Transl Res (2016) 0.75
miRNA-186 inhibits prostate cancer cell proliferation and tumor growth by targeting YY1 and CDK6. Exp Ther Med (2017) 0.75
Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma. Oncotarget (2017) 0.75
MicroRNA-206 inhibits the viability and migration of medulloblastoma cells by targeting LIM and SH3 protein 1. Exp Ther Med (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2008) 37.16
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet (2008) 32.08
Origins and Mechanisms of miRNAs and siRNAs. Cell (2009) 20.77
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
Gene regulation by transcription factors and microRNAs. Science (2008) 5.07
MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet (2010) 3.12
miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer (2010) 2.51
The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer (2011) 2.25
MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res (2011) 2.15
The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res (2011) 1.98
Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics (1995) 1.96
Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer (2011) 1.74
Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer (2010) 1.54
Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol (2010) 1.50
MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res (2012) 1.48
Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. Br J Cancer (2011) 1.45
Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res (2006) 1.44
Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res (2010) 1.44
miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-β. Biochem Biophys Res Commun (2010) 1.42
Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget (2012) 1.41
Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer (2007) 1.41
Identification of palladin isoforms and characterization of an isoform-specific interaction between Lasp-1 and palladin. J Cell Sci (2006) 1.38
Zyxin interacts with the SH3 domains of the cytoskeletal proteins LIM-nebulette and Lasp-1. J Biol Chem (2004) 1.33
Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. FEBS Lett (1995) 1.33
Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J Hum Genet (2012) 1.32
The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet (2013) 1.25
Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Int J Oncol (2013) 1.19
Phosphorylation of mouse LASP-1 on threonine 156 by cAMP- and cGMP-dependent protein kinase. Biochem Biophys Res Commun (2004) 1.12
MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. J Urol (2013) 1.10
Zyxin mediates actin fiber reorganization in epithelial-mesenchymal transition and contributes to endocardial morphogenesis. Mol Biol Cell (2009) 1.04
miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1. Int J Oncol (2012) 1.03
Prostate cancer management: 2. An update on locally advanced and metastatic disease. Postgrad Med J (2003) 0.92
Zyxin is a transforming growth factor-β (TGF-β)/Smad3 target gene that regulates lung cancer cell motility via integrin α5β1. J Biol Chem (2012) 0.89
Overexpression of LASP1 is associated with proliferation, migration and invasion in esophageal squamous cell carcinoma. Oncol Rep (2012) 0.82
[Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer]. Prog Urol (2008) 0.82
Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A (2006) 4.90
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer (2009) 3.15
miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer (2010) 3.14
Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology (2003) 2.38
The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol (2006) 2.16
Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma. Int J Urol (2014) 2.02
Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg (2010) 1.86
QTL mapping of domestication-related traits in soybean (Glycine max). Ann Bot (2007) 1.85
microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget (2012) 1.83
Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med (2007) 1.79
Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol (2013) 1.74
miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget (2011) 1.73
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res (2006) 1.73
Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget (2012) 1.72
Treatment strategy for rectal carcinoids: a clinicopathological analysis of 229 cases at a single cancer institution. J Gastroenterol Hepatol (2012) 1.71
Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol (2006) 1.68
Functional significance of aberrantly expressed microRNAs in prostate cancer. Int J Urol (2015) 1.67
Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res (2004) 1.66
Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res (2006) 1.65
Incidence of inguinal hernia after prostate surgery: open radical retropubic prostatectomy versus open simple prostatectomy versus transurethral resection of the prostate. Int J Urol (2009) 1.63
MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci (2010) 1.62
External validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology among Japanese patients. Urology (2009) 1.62
Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy. Int J Urol (2012) 1.61
miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol (2011) 1.52
Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. Int J Urol (2010) 1.50
Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol (2010) 1.50
Neoatherosclerosis and mural thrombus detection after sirolimus-eluting stent implantation. Circ J (2013) 1.48
Outcomes of shockwave lithotripsy for upper urinary-tract stones: a large-scale study at a single institution. J Endourol (2005) 1.47
Indications for gastrectomy after incomplete EMR for early gastric cancer. Gastric Cancer (2005) 1.45
Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J Orthop Res (2004) 1.43
Vascular responses in patients with and without diabetes mellitus after everolimus-eluting stent implantation. Circ J (2014) 1.42
MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol (2011) 1.42
Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget (2012) 1.41
Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res (2006) 1.41
A novel role of the C-terminus of b 0,+ AT in the ER-Golgi trafficking of the rBAT-b 0,+ AT heterodimeric amino acid transporter. Biochem J (2009) 1.41
Visceral fat accumulation is a risk factor for urinary stone. Int J Urol (2014) 1.41
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol (2008) 1.41
The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. J Biol Chem (2004) 1.40
Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol (2014) 1.39
Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers. Thromb Res (2013) 1.39
Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate-risk and high-risk prostate cancer. Int J Urol (2015) 1.39
Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol (2011) 1.39
Case of bilateral and multifocal renal cell carcinoma associated with Birt-Hogg-Dubé syndrome. Int J Urol (2014) 1.38
Genome-wide transcriptome analysis of fluoroquinolone resistance in clinical isolates of Escherichia coli. Int J Urol (2011) 1.38
Favorable vessel healing after nobori biolimus A9-eluting stent implantation-6- and 12-month follow-up by optical coherence tomography. Circ J (2014) 1.38
Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). J Hum Genet (2011) 1.35
Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem (2003) 1.34